Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell linesKeisuke Taniguchi, Akira Asai|Scientific Reports|2021Cited by 12
Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell linesKeisuke Taniguchi, Akira Asai|Research Square|2020Cited by 1